KyrunoJoin waitlist

Apolipoprotein B (ApoB)

Not yet reviewed by a clinician. This page was drafted with AI assistance from the studies cited below and checked against them by a separate automated review. It is general information, not medical advice.

Last updated November 15, 2026

Kyruno

Also called
ApoB, Apo B, Apolipoprotein B-100
Body system
Heart and blood vessels
Unit
mg/dL
Evidence grade: B

Evidence grades: A = consistent results from multiple randomized controlled trials or meta-analyses. B = at least one randomized controlled trial, or consistent large observational studies. C = observational or mechanistic evidence only. D = preliminary or conflicting evidence.

What it is

Apolipoprotein B (ApoB) is the main protein of the cholesterol-carrying particles that drive plaque build-up in the arteries, known as atherogenic lipoproteins. LDL is the best known of them. An ApoB result is a measure of how many of these particles are in the blood, which a standard LDL cholesterol result estimates only indirectly [1][2].

The National Lipid Association's 2024 expert consensus supports ApoB as an addition to the standard lipid panel. It reports that ApoB sorts people by cardiovascular risk better than LDL cholesterol, both before and during cholesterol-lowering treatment, and that when the two results disagree, risk generally follows ApoB more closely [1].

European guidelines describe ApoB as most useful where LDL cholesterol can understate risk: people with high triglycerides, diabetes, obesity or very low LDL cholesterol [2].

Typical ranges

Guidelines do not give a single normal range for ApoB. They set thresholds by a person's overall cardiovascular risk [1][2].

Source Group ApoB (mg/dL)
US risk-enhancer list, as summarized in Endotext [3] Risk-enhancing factor in adults Above 130
ESC/EAS 2019 guideline [2] Goal at very high risk Below 65
ESC/EAS 2019 guideline [2] Goal at high risk Below 80
ESC/EAS 2019 guideline [2] Goal at moderate risk Below 100
National Lipid Association 2024 [1] Treatment threshold at very high risk 60
National Lipid Association 2024 [1] Treatment threshold at high risk 70
National Lipid Association 2024 [1] Treatment threshold at borderline to intermediate risk 90

The European guideline treats its ApoB goals as secondary to LDL cholesterol goals [2]. The National Lipid Association derived its ApoB thresholds from the matching LDL cholesterol thresholds and says they are less well established [1]. None of these sources gives one optimal value for everyone; which group applies to a person is a clinical judgment.

What raises it

Saturated fat in the diet

In a WHO regression analysis of 42 controlled diet studies (104 diets), ApoB was higher when saturated fat took the place of unsaturated fat or carbohydrate [4]. A diet higher in saturated or trans fat, and a ketogenic diet, are also listed among causes of raised LDL cholesterol [3].

Evidence grade: A[3][4]

Inherited cholesterol disorders

Familial hypercholesterolemia raises LDL cholesterol through inherited gene changes. One form is caused by mutations in the ApoB gene itself, which Endotext puts at about 1 in 1,000 people [3]. ApoB testing can support screening of family members when an inherited lipid disorder is found [1].

Evidence grade: C[1][3]

Other medical conditions

Hypothyroidism, nephrotic syndrome, obstructive liver disease, Cushing's syndrome, growth hormone deficiency and anorexia nervosa are among the conditions listed as raising LDL cholesterol [3]. The source lists these for LDL cholesterol and does not report ApoB separately.

Evidence grade: C[3]

Some medicines

Medicines listed as raising LDL cholesterol include glucocorticoids, cyclosporine and tacrolimus, anabolic steroids, androgen deprivation therapy, retinoids, thiazide and loop diuretics, some progestins and protease inhibitors, among others [3]. The source lists these for LDL cholesterol and does not report ApoB separately. Never stop or change a prescribed medicine because of a lab result; talk to the prescriber.

Evidence grade: C[3]

What lowers it

Replacing saturated fat with unsaturated fat

In a WHO regression analysis of 42 controlled diet studies (104 diets), replacing saturated fat with polyunsaturated fat lowered ApoB the most, monounsaturated fat came next, and carbohydrate lowered it least [4].

Evidence grade: A[4]

Psyllium fiber

A systematic review of 28 randomized trials (1,924 people with and without high cholesterol, at a median of about 10 g of psyllium a day) pooled the trials that measured ApoB and found it fell by 0.05 g/L (about 5 mg/dL) on average, with a 95% confidence interval of 0.03 to 0.08 g/L. The authors rated this result high-quality evidence [5].

Evidence grade: A[5]

Cholesterol-lowering medicines

The National Lipid Association names drug treatment, alongside diet and other lifestyle changes, as ways to lower ApoB [1]. Whether a medicine is needed, and which, is a decision for a clinician.

Testing

Fasting is usually not needed. A joint European consensus statement reports that ApoB is not affected by whether a person has fasted, while triglycerides and LDL cholesterol shift slightly after ordinary meals [6].

  • Pregnancy is listed among the conditions that raise LDL cholesterol, so a result taken during pregnancy may not reflect a person's usual level [3].
  • Results are reported in mg/dL or in g/L. 1 g/L equals 100 mg/dL [6].
  • ApoB is read alongside the rest of a lipid panel and a person's overall risk, not on its own [1][2].

Notes

Talk to a clinician about a result above 130 mg/dL or above the range printed by your lab, a result above the goal for your risk group, or a known inherited cholesterol disorder in your family [1][2][3]. Talk to the prescriber before changing any prescribed medicine. Whether and when to repeat the test is a clinician's call.

This page is general information, not medical advice. Evidence grades use Kyruno's A to D scale.

This page is general information, not medical advice. Talk to a qualified clinician about your own results and before changing supplements or medication.

References

  1. Soffer DE, Marston NA, Maki KC, Jacobson TA, Bittner VA, Peña JM, et al.. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. Journal of Clinical Lipidology (2024) · PMID: 39256087
  2. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al.. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal (2020) · PMID: 31504418
  3. Feingold KR. Approach to the Patient with Dyslipidemia. Endotext (updated June 25, 2025) (2025)
  4. Mensink RP. Effects of saturated fatty acids on serum lipids and lipoproteins: a systematic review and regression analysis. World Health Organization (ISBN 978 92 4 156534 9) (2016)
  5. Jovanovski E, Yashpal S, Komishon A, Zurbau A, Blanco Mejia S, Ho HVT, et al.. Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition (2018) · PMID: 30239559
  6. Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, et al.. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points. A joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. European Heart Journal (2016)